Suraxavir marboxil

Suraxavir marboxil
Identifiers
  • [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxospiro[5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-6,1'-cyclopropane]-11-yl]oxymethyl methyl carbonate
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC29H25F2N3O7S
Molar mass597.59 g·mol−1
3D model (JSmol)
  • COC(=O)OCOC1=C2C(=O)N3CC4(CC4)OC[C@H]3N(N2C=CC1=O)[C@H]5C6=C(CSC7=CC=CC=C57)C(=C(C=C6)F)F
  • InChI=InChI=1S/C29H25F2N3O7S/c1-38-28(37)40-15-39-26-20(35)8-11-33-25(26)27(36)32-14-29(9-10-29)41-12-22(32)34(33)24-16-6-7-19(30)23(31)18(16)13-42-21-5-3-2-4-17(21)24/h2-8,11,22,24H,9-10,12-15H2,1H3/t22-,24+/m1/s1
  • Key:IVHSRYSBKJOVJK-VWNXMTODSA-N

Suraxavir marboxil is an investigational new drug that is being evaluated by Jiangxi Qingfeng Pharmaceutical for the treatment of influenza virus infection.[1] It is an inhibitor or the cap-dependent RNA-dependent RNA polymerase of the influenza A and B virus.[1][2][3][4]

Suraxavir marboxil is a prodrug that is metabolized to the active drug suraxavir (GP1707D07).[5]

References

  1. 1 2 "Suraxavir marboxil". AdisInsight. Springer Nature Switzerland AG. Retrieved 5 July 2026.
  2. ↑ Zhou J, Yan S, Zhao Y, Zhang H, Wang N (May 2026). "A phase I study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of suraxavir marboxil: a novel oral antiviral for influenza". Antimicrobial Agents and Chemotherapy. 70 (5) e01668-25: e0166825. doi:10.1128/aac.01668-25. PMC 13148040. PMID 41870058.
  3. ↑ Li Y, Zhang J, He F, Cao C, Zhan Y, Zhong N, et al. (February 2026). "Anti-influenza drugs targeting trimeric RNA polymerase complex: From development to clinics". Acta Pharmaceutica Sinica. B. 16 (2): 728–745. doi:10.1016/j.apsb.2025.11.033. PMC 12891864. PMID 41685158.
  4. ↑ Anastassopoulou C, Panagiotopoulos AP, Ranellou K, Mariolis I, Tsakris A (February 2026). "Antiviral strategies against H5N1: current options and emerging therapeutics". Infection. 54 (1): 25–39. doi:10.1007/s15010-025-02657-y. PMID 41105303.
  5. ↑ Han M, Cui G, Zhao Y, Zuo X, Wang X, Zhang X, et al. (2024). "Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism". Frontiers in Pharmacology. 15 1505557. doi:10.3389/fphar.2024.1505557. PMC 12022903. PMID 40291342.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.